Communiqués Nektar Therapeutics

Actions

NKTR

US6402683063

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 21/08/2026			Varia. 5j.	Varia. 1 janv.
74,02 ^USD	-0,68%		+1,37%	+75,07%

14/08	Transcript : Nektar Therapeutics, Q2 2026 Earnings Call, Aug 13, 2026
13/08	Nektar Therapeutics : réduction de la perte nette au deuxième trimestre malgré un repli du chiffre d'affaires	MT

Communiqués

13/08	Nektar: Q2 Earnings Snapshot	AQ
13/08	Nektar Therapeutics Announces Second Quarter 2026 Financial Results	PR
29/07	Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets	PR
24/07	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
21/07	Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis	PR
26/06	Nektar Therapeutics : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PU
03/06	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
28/05	Nektar Therapeutics : to Participate in the 2026 Jefferies Global Healthcare Conference in New York	PU
07/05	Nektar: Q1 Earnings Snapshot	AQ
07/05	Nektar Therapeutics Reports First Quarter 2026 Financial Results	PR
04/05	NKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026	NE
02/05	NKTR CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026	NE
01/05	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
29/04	Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets	PR
28/04	NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026	NE
25/04	NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026	NE
23/04	Nektar Therapeutics Class Action Reminder – Robbins LLP Encourages NKTR Investors to Contact the Firm for Information About Their Rights	BU
23/04	Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares	PR
23/04	NKTR CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026	NE
22/04	Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering	PR
21/04	NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline	NE
20/04	Nektar Therapeutics Announces Proposed Public Offering	PR
20/04	NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026	NE
20/04	Nektar Therapeutics : Analyst and Investor Event with Alopecia Areata Experts Presentation (802e33)	PU
20/04	52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin	PR